In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inhaled Insulin: Being First Isn't Necessarily Best

Executive Summary

The early bird may get the worm, but it's the second mouse that finds the cheese. This has proven true many times in the drug industry in the past. It may prove true once again with inhaled insulin.

You may also be interested in...



Insulin Delivery: Still Waiting to Exhale

After the commercial failure of Exubera, is inhaled insulin dead? Not at all. Exubera failed for very specific reasons: a cumbersome device, non-standard dosing, and no real clinical utility. The Exubera snafu has eroded the commercial value of inhaled insulin, but Nektar may be the best-positioned company currently competing in the inhaled insulin space. Nektar can afford to re-partner its version for less, because Pfizer has already paid for the bulk of the drug development work.

Exubera's Problem: It's Still Just Insulin

Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.

Exubera's Problem: It's Still Just Insulin

Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

IV002487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel